Jerome D. Cohen, MD, FACC, FACP


Click here to start

Table of Contents

Jerome D. Cohen, MD, FACC, FACP

Background and Rationale for OTC Pravachol

Risk is Graded and Continuous Over Broad Range MRFIT (n=361,662)

Significant Proportion of Coronary Events Occur in Individuals with TC 200-240 mg/dl (MRFIT)

NCEP Guidelines - CHD Risk Factors Other Than LDL-C

Rationale for OTC Therapy

Rationale for OTC Therapy

Major Pravastatin Clinical Outcome Trials

WOSCOPS: Baseline Lipids and Outcome

CARE AND LIPID Baseline Lipids and Events*

Indications for Pravachol

Rationale for Pravachol OTC: Safety

PPT Slide

Author: mmedia3